Table 2.
The follow-up protocols for various guidelines.
| Guideline | Follow-Up Schedules | |||
|---|---|---|---|---|
| PSA | DRE | MRI | Repeat Biopsy | |
| AUA [8] | not more frequently than every 6 months | every 1–2 years | increase in serial PSA, new DRE abnormalities, or clinical progression | increase in serial PSA, new DRE abnormalities, or clinical progression |
| EAU [9] | every 6 months | every 12 months | - | every 3 years for 10 years |
| NCCN [10] | every 6 months | every 12 months | every 12 months; | every year |
| JUA [17] | for first 2 years: every 3 months 3rd year onwards: every 6 months |
every 6 months | additional MRI if not performed at diagnosis *, if PSA DT <10 years **, or prior to repeat biopsy ** | at 1 year after diagnosis, every 3 years thereafter, and every 5 years after 10 years |
PSA, prostate-specific antigen; DRE, digital rectal examination; MRI, magnetic resonance imaging; PSA-DT, PSA doubling time. * Perform targeted biopsy if the positive region is present to confirm that it meets eligibility criteria; ** perform targeted biopsy and systematic biopsy if the positive region is present.